Hypercholesterolaemia and CHD Nutritional, Metabolic, Endocrine Hypercholesterolaemia and CHD
Conditions
Interventions
Double-blind study involving 6 weeks treatment with a once daily dose of atorvastatin (10 mg) plus either ezetimibe (10 mg) or matching ezetimibe placebo. Blood samples will be collected prior to trea
Sponsors
Schering-Plough UK Ltd
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: Male or female subjects aged 18-75 with screening low-density lipoprotein cholesterol (LDL-C) between 3.3 and 4.9 mmol/L
Exclusion criteria
Exclusion criteria: Not provided at time of registration
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Not provided at time of registration | — |
Secondary
| Measure | Time frame |
|---|---|
| Not provided at time of registration | — |
Countries
United Kingdom
Outcome results
None listed